OPEN END TURBO LONG - ROCHE GS Stock

Certificat

DE000MF13954

Market Closed - Börse Stuttgart 03:11:19 2024-06-07 pm EDT
8.64 EUR +3.10% Intraday chart for OPEN END TURBO LONG - ROCHE GS
Current month+15.82%
1 month+31.11%
Date Price Change
24-06-07 8.64 +3.10%
24-06-06 8.38 +3.33%
24-06-05 8.11 +1.63%
24-06-04 7.98 +3.91%
24-06-03 7.68 +2.95%

Delayed Quote Börse Stuttgart

Last update June 07, 2024 at 03:11 pm EDT

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Morgan Stanley
WKN MF1395
ISINDE000MF13954
Date issued 2017-04-06
Strike 157.2 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 10.16
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 24.5
Lowest since issue 4.48

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
242.6 CHF
Average target price
277.5 CHF
Spread / Average Target
+14.40%
Consensus